StockNews.com upgraded shares of Quest Diagnostics (NYSE:DGX – Free Report) from a hold rating to a buy rating in a research report released on Thursday morning. Other equities research analysts have ...
What Happened: Kuppusamy's recent move involves selling 1,775 shares of Quest Diagnostics. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on ...
The North America genetic testing services market is expected to reach US$ 4.98 billion by 2030; it is estimated to register a CAGR of 15.2% from 2022 to 2030 by major factors driving includes the ...
By combining advanced diagnostics, personalized coaching, and AI-powered health tools, this partnership offers a robust, first-of-its-kind solution for employees to proactively manage their health and ...